(Reuters) - The U.S. Food and Drug Administration approved Bayer AG's therapy for the most common form of hemophilia, about three weeks after the treatment got the green signal in Europe, the company said on Thursday.
http://ift.tt/xePdMM
from Reuters: Health News
via
animenewspro
Aucun commentaire:
Enregistrer un commentaire